Karyopharm Narrows Q4 Loss to $2.23 Per Share, Beats Revenue Forecasts
Karyopharm posted a Q4 GAAP loss of $2.23 per share versus the consensus $2.26-per-share loss estimate, narrowing from a $3.60-per-share deficit year-over-year. Quarterly revenues exceeded forecasts.
1. Q4 Financial Results
Karyopharm reported a Q4 GAAP net loss of $2.23 per share, improving from a $3.60-per-share loss in the year-ago quarter and beating consensus estimates of a $2.26-per-share loss. The company also delivered revenue figures that topped analyst forecasts, underscoring continued progress in operational execution.
Related News
C
SpaceX Reveals $1.45B Bitcoin Stake Ahead of $1.75T IPO
C•
VBCH
Vanguard’s BondBuilder Suite Amasses $242M in Two Months, Fuels $70B ETF Segment
VBCH•
MSFT
Microsoft’s AI Spending Drives 50% of Nvidia’s $38 B Data Center Revenue
MSFT•
HOOD
Robinhood Secures $3B Wells Fargo TradePMR Team, CFO to Present May 27
HOOD•
META
Manus Founders Seek $1B Raise to Unwind Meta's $2B AI Acquisition
META•
Sources
FZ